Study of Everolimus (RAD001) in Combination With Lenalidomide

Phase 1 Completed 44 enrolled Emory University Celgene Corporation · collab Novartis · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to study the combination of two anticancer drugs, everolimus (RAD001) and lenalidomide in patients whose cancer is no longer responding to standard treatment or patients who are unable to tolerate the standard treatment for their cancer.

Timeline

Start: 2010-09-09
Primary completion: 2020-11-05
Completion: 2020-11-05

Publications

Harvey RD, Carthon BC, Lewis C, Hossain MS, Zhang C, Chen Z, Harris WB, Alese OB, Shaib W, Bilen MA, Lawson DH, Wu C, Steuer CE, El-Rayes BF, Khuri FR, Lonial S, Waller EK, Ramalingam SS, Owonikoko TK. Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma. Br J Cancer. 2020 Oct;123(8):1228-1234. doi: 10.1038/s41416-020-0988-2. Epub 2020 Jul 24.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Everolimus	Small molecule	5 mg	Oral
Subject	Everolimus	Small molecule	10 mg	Oral
Subject	Lenalidomide	Other / unclassified	10 mg	Oral
Subject	Lenalidomide	Other / unclassified	15 mg	Oral
Subject	Lenalidomide	Other / unclassified	20 mg	Oral
Subject	Lenalidomide	Other / unclassified	25 mg	Oral

Study of Everolimus (RAD001) in Combination With Lenalidomide

Summary

Timeline

Publications

Drugs

Indications